市場調査レポート

商品コード

1510388

網膜疾患治療の市場規模、シェア、成長分析：タイプ別、剤形別、流通チャネル別、地域別 - 産業予測、2024-2031年

Retinal Disorder Treatment Market Size, Share, Growth Analysis, By Type(Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年07月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

網膜疾患治療の市場規模は2022年に25億米ドルと評価され、予測期間（2024-2031年）のCAGRは8.50%で、2023年の27億1,000万米ドルから2031年には52億1,000万米ドルに成長する見通しです。

網膜疾患治療市場はヘルスケアの中でもダイナミックで急速に発展している分野であり、視力に影響を及ぼす様々な網膜疾患の診断と管理に焦点を当てています。市場に影響を与える主な動向としては、人口の高齢化と糖尿病罹患率の増加による加齢黄斑変性（AMD）、糖尿病網膜症、網膜静脈閉塞症の有病率の上昇が挙げられます。これらの疾患は、治療しなければ視力障害や失明につながる可能性があり、効果的な治療に対する需要が高まっています。重要な開発には、抗VEGF薬、遺伝子治療、幹細胞治療などの新規治療が含まれます。ルセンティスやエイレアなどの抗VEGF薬は、湿性AMDや糖尿病性網膜症の治療に革命をもたらし、硝子体内注射による治療成績の向上をもたらしています。遺伝子治療は、特定の遺伝性網膜疾患に対して、長期的または永続的な視力改善を約束するものです。光干渉断層計（OCT）や眼底写真のような網膜画像技術の進歩により、診断とモニタリングが強化され、早期介入と個別化治療が可能になりました。このような技術革新にもかかわらず、治療費の高騰、継続的なモニタリングの必要性、規制や償還の問題などが課題となっています。結論として、網膜疾患治療市場は、高齢化と網膜疾患有病率の増加を背景とした技術革新と成長機会を特徴としています。継続的な研究開発がさらなる進歩をもたらし、網膜障害に罹患した人々の生活の質を向上させることが期待されます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Novartis（Switzerland）
Roche（Switzerland）
Regeneron Pharmaceuticals（USA）
Genentech（USA）
Allergan（Ireland）
Bausch Health Companies（Canada）
Alimera Sciences（USA）
Ophthotech Corporation（USA）
Spark Therapeutics（USA）
Kodiak Sciences（USA）
Santen Pharmaceutical（Japan）
Bayer AG（Germany）
Regenxbio（USA）
Chengdu Kanghong Pharmaceutical Group（China）
Graybug Vision（USA）
Apellis Pharmaceuticals（USA）
Adverum Biotechnologies（USA）
Clearside Biomedical（USA）
Acucela Inc.（USA）
PanOptica, Inc.（USA）
Opthea Limited（Australia）
Oxurion NV（Belgium）
Kala Pharmaceuticals（USA）
Hemera Biosciences（USA）
Tyrogenex（USA）

Product Code: SQMIG35I2302

Retinal Disorder Treatment Market size was valued at USD 2.50 Billion in 2022 and is poised to grow from USD 2.71 Billion in 2023 to USD 5.21 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

The retinal disorder treatment market is a dynamic and rapidly evolving sector within healthcare, focused on diagnosing and managing various vision-affecting retinal conditions. Key trends influencing the market include the rising prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion due to aging populations and increasing diabetes rates. These conditions can lead to vision impairment or blindness if untreated, driving demand for effective treatments. Significant developments include novel therapies like anti-VEGF drugs, gene therapies, and stem cell therapies. Anti-VEGF drugs, such as Lucentis and Eylea, have revolutionized treatments for wet AMD and diabetic retinopathy, offering improved outcomes through intravitreal injections. Gene therapies promise long-lasting or permanent vision improvement for certain inherited retinal disorders. Advancements in retinal imaging technologies, like optical coherence tomography (OCT) and fundus photography, have enhanced diagnosis and monitoring, enabling earlier intervention and personalized treatments. Despite these innovations, challenges include high treatment costs, the need for ongoing monitoring, and regulatory and reimbursement issues. In conclusion, the retinal disorder treatment market is characterized by innovation and growth opportunities, driven by an aging population and increasing retinal condition prevalence. Continued research and development are likely to bring further advancements, improving the quality of life for those affected by retinal disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disorder Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disorder Treatment Market Segmental Analysis

The global retinal disorder treatment market is segmented on the basis of type, dosage form, distribution channel and region. By type, the market is segmented into Macular Degeneration (Dry Macular Degeneration, Wet Macular Degeneration), Diabetic Retinopathy, and Others. By dosage form, the market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. By distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Retinal Disorder Treatment Market

The aging population significantly drives the retinal disorder treatment market, as older individuals are more prone to conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the elderly population on the rise, the prevalence of these disorders is expected to increase, thereby boosting demand for treatments and therapies. Additionally, technological advancements in ophthalmic treatments, such as anti-VEGF therapies and advanced retinal imaging techniques, have enhanced the diagnosis and management of retinal disorders, offering more effective and less invasive treatment options, leading to better patient outcomes.

Restraints in the Retinal Disorder Treatment Market

High treatment costs for retinal disorders, including expensive anti-VEGF therapies and surgical procedures, significantly restrain the market. These costs can limit access to treatment, especially in regions with limited healthcare resources or inadequate insurance coverage. Additionally, the effective treatment of retinal disorders requires specialized ophthalmologists and retinal surgeons. However, a shortage of these skilled professionals in certain areas further impedes timely access to necessary treatments for patients.

Market Trends of the Retinal Disorder Treatment Market

Significant advancements in retinal imaging and diagnostic technologies, including optical coherence tomography (OCT) and adaptive optics, have greatly improved the early detection and diagnosis of retinal disorders, allowing for timely treatment to prevent further vision loss. The integration of AI and machine learning algorithms into retinal imaging has further enhanced diagnostic accuracy and efficiency, benefiting healthcare providers. Concurrently, the treatment landscape for retinal disorders is evolving with biologic and gene therapy approaches. These innovative treatments target the genetic causes of conditions like retinitis pigmentosa and Leber congenital amaurosis. Gene therapy, particularly, has shown promising clinical trial results and received regulatory approvals for specific conditions, offering long-term benefits by addressing genetic defects and providing hope for patients with previously untreatable disorders.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Regulatory Landscape
Patent Analysis
Pestel Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Retinal Disorder Treatment Market by Type

Market Overview
Macular Degeneration
- Dry Macular Degeneration
- Wet Macular Degeneration
Diabetic Retinopathy
Others

Retinal Disorder Treatment Market by Dosage Form

Market Overview
Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

Retinal Disorder Treatment Market by Distribution Channel

Market Overview
Hospital
Online
Retail

Retinal Disorder Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alimera Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spark Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apellis Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acucela Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PanOptica, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opthea Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxurion NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemera Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tyrogenex (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

網膜疾患治療の市場規模、シェア、成長分析：タイプ別、剤形別、流通チャネル別、地域別 - 産業予測、2024-2031年

Retinal Disorder Treatment Market Size, Share, Growth Analysis, By Type(Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

網膜疾患治療市場：タイプ別

網膜疾患治療市場：剤形別

網膜疾患治療市場：流通チャネル別

網膜疾患治療市場：地域別